These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27241174)

  • 1. Preclinical Reversal of Atherosclerosis by FDA-Approved Compound that Transforms Cholesterol into an Anti-Inflammatory "Prodrug".
    Mendelsohn AR; Larrick JW
    Rejuvenation Res; 2016 Jun; 19(3):252-5. PubMed ID: 27241174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming.
    Zimmer S; Grebe A; Bakke SS; Bode N; Halvorsen B; Ulas T; Skjelland M; De Nardo D; Labzin LI; Kerksiek A; Hempel C; Heneka MT; Hawxhurst V; Fitzgerald ML; Trebicka J; Björkhem I; Gustafsson JÅ; Westerterp M; Tall AR; Wright SD; Espevik T; Schultze JL; Nickenig G; Lütjohann D; Latz E
    Sci Transl Med; 2016 Apr; 8(333):333ra50. PubMed ID: 27053774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anchoring β-CD on simvastatin-loaded rHDL for selective cholesterol crystals dissolution and enhanced anti-inflammatory effects in macrophage/foam cells.
    He J; Zhou X; Xu F; He H; Ma S; Liu X; Zhang M; Zhang W; Liu J
    Eur J Pharm Biopharm; 2022 May; 174():144-154. PubMed ID: 35447349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Orai1 Store-Operated Calcium Channel Prevents Foam Cell Formation and Atherosclerosis.
    Liang SJ; Zeng DY; Mai XY; Shang JY; Wu QQ; Yuan JN; Yu BX; Zhou P; Zhang FR; Liu YY; Lv XF; Liu J; Ou JS; Qian JS; Zhou JG
    Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):618-28. PubMed ID: 26916730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with KLEPTOSE® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response.
    Montecucco F; Lenglet S; Carbone F; Boero S; Pelli G; Burger F; Roth A; Bertolotto M; Nencioni A; Cea M; Dallegri F; Fraga-Silva RA; Fougère L; Elfakir C; Gassner AL; Rudaz S; Parissaux X; Wils D; Salomé M; Vuilleumier N; Poggi A; Mach F
    Vascul Pharmacol; 2015 Sep; 72():197-208. PubMed ID: 25921922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Ultrasound-Responsive Theranostic Cyclodextrin-Loaded Nanoparticle for Multimodal Imaging and Therapy for Atherosclerosis.
    Mehta S; Bongcaron V; Nguyen TK; Jirwanka Y; Maluenda A; Walsh APG; Palasubramaniam J; Hulett MD; Srivastava R; Bobik A; Wang X; Peter K
    Small; 2022 Aug; 18(31):e2200967. PubMed ID: 35710979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proprotein convertase furin/PCSK3 and atherosclerosis: New insights and potential therapeutic targets.
    Ren K; Jiang T; Zheng XL; Zhao GJ
    Atherosclerosis; 2017 Jul; 262():163-170. PubMed ID: 28400053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclodextrin-mediated conjugation of macrophage and liposomes for treatment of atherosclerosis.
    Gao C; Liu C; Chen Q; Wang Y; Kwong CHT; Wang Q; Xie B; Lee SMY; Wang R
    J Control Release; 2022 Sep; 349():2-15. PubMed ID: 35779655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostaglandin E1 dose-dependently promotes stability of atherosclerotic plaque in a rabbit model.
    Bai W; Zheng X; Zhou L; Li H
    Can J Physiol Pharmacol; 2012 Feb; 90(2):131-9. PubMed ID: 22309388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the immune response in atherosclerosis: It's time for clinical trials!
    Joffre J; Ait-Oufella H
    Arch Cardiovasc Dis; 2017 Dec; 110(12):643-645. PubMed ID: 29051009
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacological activation of the melanocortin system limits plaque inflammation and ameliorates vascular dysfunction in atherosclerotic mice.
    Rinne P; Silvola JM; Hellberg S; Ståhle M; Liljenbäck H; Salomäki H; Koskinen E; Nuutinen S; Saukko P; Knuuti J; Saraste A; Roivainen A; Savontaus E
    Arterioscler Thromb Vasc Biol; 2014 Jul; 34(7):1346-54. PubMed ID: 24790139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Characteristics and Roles of Advanced Oxidation Protein Products in Atherosclerosis.
    Ou H; Huang Z; Mo Z; Xiao J
    Cardiovasc Toxicol; 2017 Jan; 17(1):1-12. PubMed ID: 27350146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polydatin for treating atherosclerotic diseases: A functional and mechanistic overview.
    Wu M; Li X; Wang S; Yang S; Zhao R; Xing Y; Liu L
    Biomed Pharmacother; 2020 Aug; 128():110308. PubMed ID: 32480216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy.
    McLaren JE; Michael DR; Ashlin TG; Ramji DP
    Prog Lipid Res; 2011 Oct; 50(4):331-47. PubMed ID: 21601592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclodextrin related drug delivery system to promote atherosclerosis regression.
    Zhang L
    Pharmazie; 2020 Dec; 75(12):619-625. PubMed ID: 33303053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voluntary Exercise Stabilizes Established Angiotensin II-Dependent Atherosclerosis in Mice through Systemic Anti-Inflammatory Effects.
    Pellegrin M; Aubert JF; Bouzourène K; Amstutz C; Mazzolai L
    PLoS One; 2015; 10(11):e0143536. PubMed ID: 26600018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition.
    Tie C; Gao K; Zhang N; Zhang S; Shen J; Xie X; Wang JA
    PLoS One; 2015; 10(11):e0142430. PubMed ID: 26555472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-inflammatory salicylate beneficially modulates pre-existing atherosclerosis through quenching of NF-κB activity and lowering of cholesterol.
    de Vries-van der Weij J; Toet K; Zadelaar S; Wielinga PY; Kleemann R; Rensen PC; Kooistra T
    Atherosclerosis; 2010 Nov; 213(1):241-6. PubMed ID: 20926077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous intake of oat bran and atorvastatin reduces their efficacy to lower lipid levels and atherosclerosis in LDLr-/- mice.
    Eussen SR; Rompelberg CJ; Andersson KE; Klungel OH; Hellstrand P; Oste R; van Kranen H; Garssen J
    Pharmacol Res; 2011 Jul; 64(1):36-43. PubMed ID: 21371558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-cyclodextrin inhibits cholesterol crystal-induced complement-mediated inflammation: A potential new compound for treatment of atherosclerosis.
    Pilely K; Bakke SS; Palarasah Y; Skjoedt MO; Bartels ED; Espevik T; Garred P
    Atherosclerosis; 2019 Apr; 283():35-42. PubMed ID: 30772772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.